Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Horizon Therapeutics Public Limited Company - Ordinary Shares (NQ: HZNP )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Oct 5, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Horizon Therapeutics Public Limited Company - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 Next >
Horizon Therapeutics plc Named a Best Company for Multicultural Women
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Announces Inaugural #RAREis Global Advocate Grant Recipients
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Announces Wanda Durant Has Joined Olympian Gail Devers to Raise Awareness of Thyroid Eye Disease Among Graves’ Disease Community
From Horizon Therapeutics plc
Via Business Wire
FDA Approves KRYSTEXXA® (pegloticase) Injection Co-Administered With Methotrexate, Expanding the Labeling to Help More People with Uncontrolled Gout Achieve a Complete Response to Therapy
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc to Release Second-Quarter 2022 Financial Results and Host Webcast on Aug. 3, 2022
From Horizon Therapeutics plc
Via Business Wire
New Analysis Finds UPLIZNA® (inebilizumab) Effective Among European Populations with Neuromyelitis Optica Spectrum Disorder (NMOSD)
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Submits Regulatory Filing for UPLIZNA® (inebilizumab) in Brazil
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Named One of the Fortune Best Workplaces in Chicago™
From Horizon Therapeutics plc
Via Business Wire
Analysis of Pooled Data from TEPEZZA® (teprotumumab-trbw) Clinical Trials Reinforces Safety Profile in People with Thyroid Eye Disease (TED)
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Named a Top Company for Executive Women
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc to Present at the Goldman Sachs 43rd Annual Global Health Care Conference
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc to Highlight Data and Education on Thyroid Eye Disease (TED) at the Endocrine Society (ENDO) 2022 Annual Conference
From Horizon Therapeutics plc
Via Business Wire
Data Presented from the MIRROR Randomized Controlled Trial Demonstrate KRYSTEXXA® (pegloticase injection) Plus Methotrexate Resulted in Significant Improvement in Efficacy and Safety (Infusion Reactions) Compared to KRYSTEXXA Monotherapy
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Wins 2022 International CSR Excellence Award for #RAREis Adoption Fund
From Horizon Therapeutics plc
Via Business Wire
Analysis from the Phase 3 N-MOmentum Study Demonstrates the Effectiveness of UPLIZNA® (inebilizumab-cdon) Among Neuromyelitis Optica Spectrum Disorder Patients with Genetic Variations
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc to Present MIRROR Randomized Controlled Trial Primary Endpoint Data at The EULAR 2022 European Congress of Rheumatology
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab (HZN-7734) for the Treatment of Alopecia Areata
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Ranked Second in Overall Corporate Reputation in U.S. PatientView Survey of Patient Groups
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Announces Dara Mann as a Healthcare Businesswomen’s Association 2022 Rising Star
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Launches Letter-Writing Campaign to Empower Those Living with Thyroid Eye Disease (TED) to Confront the Condition Head On
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics and Chicago Sky Announce Multi-Year Partnership
From Horizon Therapeutics
Via Business Wire
Horizon Therapeutics plc Reports First-Quarter 2022 Financial Results
From Horizon Therapeutics plc
Via Business Wire
Topline Data for Dazodalibep (HZN-4920) Meets Primary Endpoint in Rheumatoid Arthritis
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Launches #RAREis Global Advocate Grant Program to Support the Rare Disease Community
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Receives European Commission (EC) Approval of UPLIZNA® (inebilizumab) for the Treatment of Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD)
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Among Top Companies for Overall Corporate Reputation in 2021 Global PatientView Survey of Patient Groups Worldwide
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics and Massachusetts Institute of Technology (MIT) Solve Announce Second Annual Horizon Prize to Inspire Solutions that Improve the Quality of Life for the Global Rare Disease Community
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc to Release First-Quarter 2022 Financial Results and Host Webcast on May 4, 2022
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Named One of the Fortune 100 Best Companies to Work For®
From Horizon Therapeutics plc
Via Business Wire
New Analysis Finds UPLIZNA® (inebilizumab-cdon) Effective for People with Newly-Presenting Neuromyelitis Optica Spectrum Disorder (NMOSD)
From Horizon Therapeutics plc
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.